Everything below concerns Angiotensin IV. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-25. Numbers and descriptions here follow the published literature rather than marketing material.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic angiotensin IV analog | Peptidomimetic |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in DMSO; limited in water | Typical for small peptides |
| Storage | -20 °C, desiccated | Protect from light and moisture |
| Analytical method | HPLC with UV detection | Purity and identity checks |
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Transurethral resection of the prostate (TURP) replaced radical prostatectomy for symptomatic relief of obstruction in the middle of the 20th century because it could better preserve penile erectile function. Radical retropubic prostatectomy was developed in 1983 by Patrick Walsh. In 1941, Charles B. Huggins published studies in which he used estrogen to oppose testosterone production in men with metastatic prostate cancer. This discovery of "chemical castration" won Huggins the 1966 Nobel Prize in Physiology or Medicine. The role of the gonadotropin-releasing hormone (GnRH) in reproduction was determined by Andrzej W. Schally and Roger Guillemin, who both won the 1977 Nobel Prize in Physiology or Medicine for this work. GnRH receptor agonists, such as leuprorelin and goserelin, were subsequently developed and used to treat prostate cancer. Radiation therapy for prostate cancer was first developed in the early 20th century and initially consisted of intraprostatic radium implants. External beam radiotherapy became more popular as stronger X-ray radiation sources became available in the middle of the 20th century. Brachytherapy with implanted seeds (for prostate cancer) was first described in 1983. Systemic chemotherapy for prostate cancer was first studied in the 1970s. The initial regimen of cyclophosphamide and 5-fluorouracil was quickly joined by multiple regimens using a host of other systemic chemotherapy drugs.
The lotus roots grow in pond or river bottom soil, while the leaves float on the water's surface or are held well above it. The leaf stalks (petioles) can be up to 200 cm (6 ft 7 in) long, allowing the plant to grow in water to that depth. The peltate leaf blade or lamina can have a diameter of 80–100 cm (2 ft 7 in – 3 ft 3 in). The leaves are spaced up to 2 m (6 ft 7 in) apart along the rhizome, which can grow as much as 20 m (66 ft) in one year. The internodes are not cylindrical but swollen in the middle.
Pemetrexed is chemically similar to folic acid and is in the class of chemotherapy drugs called folate antimetabolites. It works by inhibiting three enzymes used in purine and pyrimidine synthesis—thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cells.
==== Johnson v. Zuffa ==== Based on court filings from late July 2025, the Johnson v. Zuffa antitrust lawsuit, originally filed in 2021, is proceeding, and status conference for the case is scheduled for late August 2025.
=== Marketing === Dicural was sponsored by Fort Dodge Animal Health through New Animal Drug Application (NADA) 141-096. It offers veterinarians once-per-day dosing by providing excellent tissue penetration. Difloxacin can only be obtained either from a veterinarian or by a medical prescription from a veterinarian. It is available as the hydrochloride salt in scored tablets of different strengths for easier dosing adjustments. For differentiation, the milligram strengths, 11.4 mg, 45.4 mg and 136 mg, are colored blue, white and orange, respectively. Fort Dodge Animal Health was acquired by Zoetis in 2009. In February 2012, the Municipality of Ulianopolis (State of Para, Brazil) filed a complaint against Fort Dodge Saúde Animal Ltda. (FDSAL) and five other large companies alleging that waste sent to a local waste incineration facility for destruction, but that was not ultimately destroyed as the facility lost its operating permit, caused environmental impacts requiring cleanup. The Municipality is seeking recovery of cleanup costs purportedly related to FDSAL's share of all waste accumulated at the incineration facility awaiting destruction, and compensatory damages to be allocated among the six defendants. The prosecutor granted a request for a face-to-face meeting on November 6, 2015.
Sources: en.wikipedia.org
=== Allegations of steroid use and National Baseball Hall of Fame === Bagwell was eligible for induction into the Baseball Hall of Fame for the first time in 2011. Speculation abounded that some baseball writers initially refrained from voting for Bagwell on the premise that he used performance-enhancing drugs, since most of his playing career took place during what is commonly referred to as "the steroid era." In spite of the speculation, as of 2016, no concrete evidence has surfaced linking him to the use of performance-enhancing drugs. However, one report indicates that he disclosed use of androstenedione to a Houston Chronicle reporter in 1998. At that time, neither the FDA nor MLB had banned its use. Bagwell has not been connected with any of the 104 positive samples in the 2003 survey tests that were leaked. Bagwell was not among the 89 players named in the Mitchell Report released in 2007. Longtime Atlanta Braves manager Bobby Cox said the following about Bagwell: "Jeff Bagwell was [in Houston] for so long and starred every year. For me a guy that dominated like that for one team, even in the league stats through the years. His are up there with anybody's. I would put him in right away. So he would get my vote on the first ballot." Still, in spite of the speculation that Bagwell used performance-enhancing drugs, San Francisco Chronicle sportswriter Bruce Jenkins wrote that Bagwell did not have the credentials to be in the Hall of Fame. In July 2015, he acknowledged "that many are suspicious of Bagwell—without proof, as you say.
== Research and Impact == Bhatia leverages miniaturization tools drawn from the computer industry to drive medical innovation. Her groundbreaking work has broad applications in cancer, liver, and infectious diseases, leading to significant advancements in early disease detection, human disease modeling, tissue regeneration, cell transplantation, and the development of cancer therapeutics. Bhatia's laboratory, the Laboratory for Multiscale Regenerative Technologies (LMRT), operates at the interface of living and synthetic systems, engineering micro and nanotechnologies to tackle complex human health challenges.
Under established doping control protocols, the athlete will be asked to provide a urine sample, which will be divided into two, each portion to be preserved within sealed containers bearing the same unique identifying number and designation respectively as A- and B-samples. An athlete whose A-sample has tested positive for a prohibited substance is requested an analysis of his or her B-sample after a confirmation test on sample A that delivered the same results. If the B-sample test results match the A-sample results, then the athlete is considered to have a positive test, otherwise, the test results are negative. This confirmation process ensures the safety of the individual.
The coffee tree produces fruit often referred to as a coffee cherry, but unlike the cherry, which contains a single pit, it most commonly contains two seeds with their flat sides together. The seeds are referred to as beans because of their appearance, though they are not true beans. A few coffee cherries, referred to as "peaberries" contain a single seed; they make up around 10% to 15% of all coffee beans. It is sometimes asserted that because the single bean does not need to share nutrients between two separated beans, it has a superior flavour profile with bright acidity, sweetness, and concentrated and complex flavours, but there is little evidence to support this; for example, peaberries may have been selected from high-quality beans. Coffee trees range from 5 to 10 m (16 to 33 ft) in height. As the tree gets older, it produces less fruit and slowly loses its resistance to pests and diseases. The coffee beans are in the seeds of fruits from trees and shrubs that originally grew naturally in African forests. Humans produce coffee by roasting, grinding and brewing the raw (green) coffee beans. Coffee plants are often grown in rows spaced apart depending on the desired density chosen by the farmer. Some farmers plant shade trees or cash-crop trees, such as orange trees, around them, or plant the coffee on the sides of hills to provide the conditions coffee needs to flourish.
Sources: en.wikipedia.org
American biochemist and geneticist at the NIH, who showed that UUU codes for phenylalanine, the first step in deciphering the genetic code. Nobel Prize in Physiology or Medicine (1968). Member Natl. Acad. Sci. USA. Roland Victor Norris (1888–1950). British biochemist at the Indian Institute of Science, who worked on glycogen metabolism and yeast fermentation, and later pioneered biochemistry in India. Paul Nurse FRS (President) (b. 1949). British geneticist at the Rockefeller University, who worked on control of the cell cycle. Nobel Prize in Physiology or Medicine (2001)
==== Harris lines ==== Harris lines form before adulthood, when bone growth is temporarily halted or slowed down due to some sort of stress (typically disease or malnutrition). During this time, bone mineralization continues, but growth does not, or does so at reduced levels. If and when the stressor is overcome, bone growth resumes, resulting in a line of increased mineral density visible in a radiograph. Absent removal of the stressor, no line forms. Particularly, deficiencies in protein and vitamins, which lead to delayed longitudinal bone growth, can result in the formation of Harris lines. During the process of endochondral bone growth, the cessation of osteoblastic activity results in the deposition of a thin layer of bone beneath the cartilage cap, potentially forming Harris lines. Subsequent recovery, necessary for the restoration of osteoblastic activity, is also implicated in Harris line formation. When matured cartilage cells reactivate, bone growth resumes, thickening the bony stratum. Therefore, complete recovery from periods of chronic illness or malnutrition manifests as transverse lines on radiographs. Lines tend to be thicker with prolonged and severe malnutrition. Harris line formation typically peaks in long bones around 2–3 years after birth and becomes rare after the age of 5 until adulthood. Harris lines occur more frequently in boys than in girls.
In contrast, siRNAs typically base-pair perfectly and induce mRNA cleavage only in a single, specific target. In Drosophila and C. elegans, miRNA and siRNA are processed by distinct Argonaute proteins and Dicer enzymes.
== Structure == The hypothalamus is divided into four regions (preoptic, supraoptic, tuberal, mammillary) in a parasagittal plane, indicating location anterior-posterior; and three zones (periventricular, intermediate, lateral) in the coronal plane, indicating location medial-lateral. Hypothalamic nuclei are located within these specific regions and zones. It is found in all vertebrate nervous systems. In mammals, magnocellular neurosecretory cells in the paraventricular nucleus and the supraoptic nucleus of the hypothalamus produce neurohypophysial hormones, oxytocin and vasopressin. These hormones are released into the blood in the posterior pituitary. Much smaller parvocellular neurosecretory cells, neurons of the paraventricular nucleus, release corticotropin-releasing hormone and other hormones into the hypophyseal portal system, where these hormones diffuse to the anterior pituitary.
Odi: 354,782 Moretele: 235,540 Tlhaping-Tlharo: 101,425 Ditsobotla: 135,045 Molopo: 128,383 Mankwe: 89,841 Bafokeng: 88,399 Taung: 134,277 Thaba 'Nchu: 49,053 Lehurutshe: 62,901 Madikwe: 52,268 Ganyesa: 47,036 Major cities and towns in Bophuthatswana included:
Sources: en.wikipedia.org
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.
No major drug regulatory agency has approved dihexa for human use. Published human clinical trials are absent, so its safety and efficacy are not established. It is commonly sold for laboratory research only.
It was developed from research on angiotensin IV analogs and peptide stability. The goal was to find compounds with better brain penetration and metabolic resistance. Early studies used rodent models rather than human participants.
The lyophilized powder is generally stored at -20 °C or lower, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data may vary by formulation and purity.